Article metrics

Download PDFPDF
Concise report
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

 

Online download statistics by month:

Online download statistics by month: June 2014 to August 2021

AbstractFullPdf
Jun 20144342576
Jul 201448693132
Aug 20141255159
Sep 20141083851
Oct 20142532143
Nov 201495662111
Dec 20143914281
Jan 20152904766
Feb 20151442939
Mar 20151173230
Apr 2015842226
May 2015592217
Jun 2015551313
Jul 2015482319
Aug 2015551920
Sep 2015791011
Oct 2015641214
Nov 2015541319
Dec 2015661315
Jan 2016581817
Feb 2016381212
Mar 201648411
Apr 20163699
May 2016481419
Jun 201638810
Jul 20162476
Aug 20163096
Sep 2016921613
Oct 2016622625
Nov 2016441516
Dec 201642711
Jan 2017482019
Feb 201743129
Mar 2017521611
Apr 20173475
May 2017501111
Jun 201744177
Jul 201778514
Aug 2017137119
Sep 201793811
Oct 20171011114
Nov 2017801318
Dec 20175685
Jan 20181311512
Feb 20181021912
Mar 201811598
Apr 20186897
May 20184454
Jun 20188285
Jul 20185567
Aug 20188742
Sep 20188253
Oct 20183220
Nov 20185885
Dec 20182910
Jan 20197187
Feb 20194485
Mar 20193132
Apr 20194336
May 20194844
Jun 20194244
Jul 201948148
Aug 20198265
Sep 20193431
Oct 20195832
Nov 20196842
Dec 20198433
Jan 202077104
Feb 20204033
Mar 20203791
Apr 20204143
May 202084116
Jun 20207075
Jul 20207153
Aug 20204054
Sep 20206953
Oct 20207173
Nov 202011194
Dec 20207086
Jan 20214252
Feb 2021109105
Mar 20219645
Apr 20214510
May 20212221
Jun 20211183
Jul 2021502
Aug 2021862
Total790111441309